CA-SOLIDIGM
6.8.2024 17:22:27 CEST | Business Wire | Press release
Today, Solidigm, a leading provider of innovative NAND flash memory solutions, announced the launch of the SolidigmTM D7-PS1010 and D7-PS1030 data center solid-state drives (SSDs). As the fastest PCIe 5.0 SSDs1 shipping in volume today, these drives are well suited for the IO intensity found in modern mainstream, mixed, and write-centric workloads.
“The Solidigm D7-PS1010 and D7-PS1030 SSDs were meticulously engineered to meet the increasingly demanding IO requirements across a range of workloads such as general-purpose servers, OLTP, server-based storage, decision support systems and AI/ML,” said Greg Matson, Senior Vice President of Strategic Planning and Marketing at Solidigm. “In a world where every watt counts, these drives are PCIe 5.0 done right, not only delivering industry-leading four-corner performance,2 but also up to 70% better energy efficiency compared to similar drives by other manufacturers.3”
Available in E3.S and U.2 form factors, the newest Solidigm SSDs come in a range of capacities and endurance options and are a strong extension to the company’s portfolio of best-in-industry storage for AI.
D7-PS1010
A standard endurance (SE) drive, the Solidigm D7-PS1010 is available in 1.92TB, 3.84TB, 7.68TB, and 15.36TB capacities. Over a 5-year period, the SE models provide 1.0 drive writes per day (DWPD) and boast substantial maximum lifetime program/erase cycles, with 28 petabytes written (PBW) for the 15.36TB variant. In server-based storage solutions, the D7-PS1010 can accelerate sequential write throughput up to 37 percent faster than drives with similar specifications.4 Offering a balance of performance and capacity, this drive is ideal for a wide range of mainstream applications.
D7-PS1030
A mid-endurance (ME) drive, the Solidigm D7-PS1030 is available in 1.6TB, 3.2TB, 6.4TB, and 12.8TB capacities and offers an impressive 70 PBW for the 12.8TB variant. When placed in an all-flash performance tier for AI workloads, the D7-PS1030 helps overcome hard disk drive (HDD) performance, endurance, and reliability limitations. With write performance more than double that of the previous generation Solidigm drive,5 the D7-PS1030 is particularly suited for operations requiring write-intensive usages such as caching and checkpointing.
The new drives are built to excel at every stage of the AI data pipeline and deliver up to 50 percent higher throughput in certain pipeline phases6 compared to similar drives in their class. These SSDs can be deployed as GPU direct attach drives in GPU servers or as part of a high-performance all-flash tier supporting lower-performing HDDs in network attach storage configurations.
“As AI workloads continue to surge, storage performance becomes critical,” said Ace Stryker, Director of Market Development at Solidigm. “The Solidigm D7-PS1010 and D7-PS1030 are a game-changer for AI-driven enterprises, capable of outperforming competitors at critical stages of the AI pipeline.”
With this launch, Solidigm continues its commitment to delivering industry-leading quality and reliability. By employing methodologies like testing to zero tolerance for data errors,7 built-in redundancies, enhanced power loss management, and engineering for performance consistency over the life of the drive,8 these SSDs far surpass required industry specifications and common practices. Combined with new OCP-compliant thermal management capabilities, and new security capabilities such as secure boot and data at rest protection and attestation, the D7-PS1010 and D7-PS1030 drives are designed to be deployed with utmost confidence in cloud and enterprise usages.
For more information on how Solidigm D7-PS1010 and Solidigm D7-PS1030 drives can help you power your workloads, visit our website.
About Solidigm
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Originating from the sale of Intel’s NAND and SSD business, Solidigm became a standalone U.S. subsidiary of semiconductor leader SK hynix in December 2021. Headquartered in Rancho Cordova, California, Solidigm is powered by the inventiveness of team members in 13 locations around the world. For more information, please visit solidigm.com and follow us on Twitter and on LinkedIn. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm).
______________________
1 Comparing product specifications and measured real-life workload performance across widely shipping PCIe 5.0 data center SSDs at the industry’s highest volume capacity point of 3.84TB (using Solidigm 2023 and 2024 shipments as industry representative data).
2 Four-corner comparison data is based on publicly available information from Samsung, Kioxia, and Micron.
3 Comparing 7.68TB, Samsung PM1743 and Solidigm D7-PS1010. Power is measured using Quarch Technology. Solidigm D7-PS1010 (128KB SW QD128 IOPS/Watt 3,874), Samsung PM1743 (128KB SW QD128 IOPS/Watt 2,272).
4 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. Comparing SolidigmTM D7-PS1010 3.84TB (128KB Seq Write QD128 8.2 MB/s) vs Samsung PM1743 3.84TB (128KB Seq Write QD128 6.0 MB/s).
5 As compared to previous generation Solidigm™ D7-P5520 and D7-P5620.
6 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. SolidigmTM D7-PS1010 7.68TB (32KB SW QD32 9.03GB/s 113us) vs Samsung PM1743 7.68TB (32K SW QD32 6.03GB/s 170us).
7 Solidigm drives are tested to 1E-18 under full range of conditions and cycle counts throughout the life of the drive which is 100X higher than 1E-16 specified in JEDEC – Solid State Drive Requirements and Endurance Test Method (JESD218). https://www.jedec.org/standards-documents/focus/flash/solid-state-drives.
8 Refer to SolidigmTM D7-PS1010 product specifications for IOPS consistency. Solidigm expects up to 5% variation in throughput between drive-to-drive runs. IOPS variability measured after adjusting SSD cycle limit to simulate end of life behavior. Results are estimated or simulated. Actual results may vary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806563458/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom